ClinicalTrials.gg
CompletedNCT02499146Updated Feb 11, 2026Results posted

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

A Phase 1 interventional study of Palbociclib and Letrozole in Advanced Breast Cancer, sponsored by Pfizer. Completed at 7 sites in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Enrollment
97th of 111
26 · median 100
Started
2015
with 12 others
Phase 1
14 of 111
3 open now
Registered
23rd of 111
by date
Lead sponsor
10 of 111
Pfizer

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 97th largest by enrollment, is one of 13 that started in 2015, is one of 14 in phase 1, and was the 23rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

As part of the global clinical development program for Palbociclib, studies are planned in cancer patients in China. An assessment of Palbociclib pharmacokinetics in Chinese patients, as required by the Chinese Health Authorities, is therefore warranted. In addition, safety and efficacy will be also evaluated.

The single and multiple 125 mg oral dose pharmacokinetics of Palbociclib will be characterized.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • Palbociclib
  • PD-0332991
  • pharmacokinetics
  • breast cancer patients
  • Chinese
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ER(+), (-), adult (ages 18-65 years, inclusive) Chinese women with proven diagnosis of adenocarcinoma of the breast with evidence locoregionally recurrent or disease not amenable to resection or radiation therapy with curative intent and for whom chemotherapy is not clinically indicated.

    a. Postmenopausal women: i. Prior bilateral surgical oophorectomy; or ii. Medically confirmed post-menopausal status defined as spontaneous cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause b. Documentation of or cytologically confirmed diagnosis of: i. ER(+) breast cancer. c. Documentation of HER2(-) breast cancer. d. Previously untreated with any systemic anti cancer therapy for their locoregionally recurrent or metastatic ER+ disease.

  • as defined per v.1.1 or bone-only disease. - Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measurable if disease progression at the treated site after completion of therapy is clearly documented.

Exclusion criteria

Exclusion Criteria:

  • -positive tumor as defined by documentation of erbB-2 gene amplification by FISH (as defined by a HER2/CEP17 ratio ≥2) or chromogenic in situ hybridization (CISH, as defined by the manufacturer's kit instruction) or documentation of HER2 overexpression by IHC (defined as IHC3+, or IHC2+ with FISH or CISH confirmation) based on local laboratory results
  • Patients with advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term (including patients with massive uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and over 50% liver involvement).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Combination therapy of palbociclib and letrozole

    Drug: Palbociclib · Drug: Letrozole

Interventions

  • 125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle

  • 2.5 mg , orally once daily (continuously)

06

What researchers measure

Primary outcomes

  1. Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib

    Cmax of palbociclib in the single-dose part (lead-in phase) was observed directly from data.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  2. Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib

    Tmax for palbociclib in the single-dose part (lead-in phase) was observed directly from data as time of first occurrence.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  3. Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib

    AUC10 for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, and 10 hours post dose

  4. Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib

    AUC24 is AUCtau, where the dosing interval (tau) is 24 hours. AUC24 in the single-dose part (lead-in phase) for palbociclib was obtained by linear/log trapezoidal method.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose

  5. Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib

    AUClast for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  6. Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib

    AUCinf for palbociclib in the single-dose part (lead-in phase) was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the rate constant for terminal phase obtained by linear regression of the log-linear concentration-time curve.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  7. Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib

    Kel for palbociclib in the single-dose part (lead-in phase) was obtained by linear regression of the log-linear concentration-time curve.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  8. Single-dose PK: Mean Residence Time (MRT) for Palbociclib

    MRT for palbociclib in the single-dose part (lead-in phase) was calculated as AUMCinf/AUCinf, where AUMCinf was area under the first moment curve from time 0 to infinity.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  9. Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib

    t1/2 for palbociclib in the single-dose part (lead-in phase) was calculated as Loge(2)/kel.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  10. Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib

    CL/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/AUCinf.

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  11. Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib

    Vz/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/(AUCinf \* kel).

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose

  12. Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib

    Css,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21

  13. Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib

    Css,min of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21

  14. Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib

    AUCss,tau of palbociclib in the multiple-dose part (Cycle 1) was determined by linear/log trapezoidal method.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21

  15. Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib

    Css,av of palbociclib in the multiple-dose part (Cycle 1) was calculated as AUCss,tau/tau, where tau was 24 hours.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21

  16. Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib

    Tss,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data as time of first occurrence within tau (=24 hours) at steady state.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21

  17. Multiple-dose PK: Vz/F for Palbociclib

    Vz/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/(AUCss,tau \* kel), where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state and kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21

  18. Multiple-dose PK: t1/2 for Palbociclib

    t1/2 of palbociclib in the multiple-dose part (Cycle 1) was calculated as ln (2)/kel, where kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21

  19. Multiple-dose PK: CL/F for Palbociclib

    CL/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/AUCss,tau, where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21

  20. Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib

    PTF of palbociclib in the multiple-dose part (Cycle 1) was determined as (Css,max - Css,min)/Css,av. Css,max and Css,min were observed directly from data while Css,av was calculated as AUCss,tau/tau, where tau was 24 hours.

    Time frame: Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21

  21. Observed Accumulation Ratio (Rac) for Palbociclib

    Rac of palbociclib was determined as AUCss,tau/AUCsd,tau, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCsd,tau was AUC24 from single-dose part (lead-in phase).

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21

  22. Steady State Accumulation Ratio (Rss) for Palbociclib

    Rss of palbociclib was calculated as AUCss,tau/AUCinf, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCinf was from single-dose part (lead-in phase).

    Time frame: Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24 hours post dose on Day 21

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator.

    Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)

  2. Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade

    An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. AEs were graded by NCI CTCAE version 4.0: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.

    Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)

  3. Number of Participants With Laboratory Test Abnormalities

    The number of participants with the following laboratory test abnormalities meeting any of the Grades 1 to 4 criteria per the NCI CTCAE (version 4.0) is summarized: anemia, lymphopenia, neutropenia, platelet count decreased, white blood cell (WBC) decreased, alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, bilirubin (total) increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4=life-threatening. One participant might had more than 1 laboratory test abnormality.

    Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)

  4. Number of Participants Meeting the Categorical Summarization Criteria for QTcF and QTcB Parameters

    QT interval (time from electrocardiogram \[ECG\] Q wave and the end of the T wave corresponding to electrical systole) corrected for heart rate using Fridericia's formula was QTcF and QT interval corrected for heart rate using Bazett's formula was QTcB. Categorical summarization criteria for QTcF and QTcB were as follows: 1) maximum absolute value of \<450 milliseconds (msec), \>=450 to \<=480 msec, \>=481 to \<=500 msec, or \>=500 msec; 2) maximum increase from baseline of \<30 msec, \>=30 to \<60 msec, or \>=60 msec. One participant could be reported under more than 1 categorical summarization criteria for QTcF and QTcB Parameters.

    Time frame: From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)

  5. Progression-Free Survival (PFS)

    PFS was defined as the time from Cycle 1 Day 1 (C1D1) to date of first documentation of disease progression (PD) or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)

  6. Percentage of Participants Achieving Objective Response (Objective Response Rate [ORR])

    ORR was the percentage of participants with an objective response (complete response \[CR\] or partial response \[PR\]). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions.

    Time frame: From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)

  7. Percentage of Participants Achieving Disease Control (Disease Control Rate [DCR])

    Disease control (DC) = CR, PR or stable disease (SD) \>= 24 weeks according to RECIST version 1.1 recorded from C1D1 until disease progression or death due to any cause. CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). SD: Does not qualify for CR, PR or progression. PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or appearance of new unequivocal malignant lesions.

    Time frame: From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)

  8. Duration of Response

    Duration of response was the time from first documentation of CR or PR to date of first documentation of PD or death for the participants with an objective response (CR or PR). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions. Kaplan-Meier method was used.

    Time frame: From first documentation of CR or PR to date of first documentation of objective progression or death, whichever occurred first (up to maximum of 471 weeks of treatment exposure)

  9. 1-Year PFS Probability

    PFS was defined as the time from C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the RECIST (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. One-year PFS probability was defined as the probability (expressed as percentage) of PFS at 1 year after C1D1. PFS probability was determined using the Kaplan-Meier method.

    Time frame: 1 year

  10. Trough Plasma Concentration of Letrozole

    Plasma samples were analyzed for letrozole concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric (HPLC/MS/MS) method.

    Time frame: pre-dose of Cycle 1 Days 19, 20, 21 and Cycle 2 Day 1

  11. Ratio Over Baseline for Skin Biomarker Phosphorylated Retinoblastoma Protein (pRb) Expression

    The pRb was one of the skin biomarkers and samples were assayed using immunohistochemistry (IHC) method. Ratio over baseline was calculated by dividing the H-score value for pRb at each specified time point by baseline value. The H-score value, which could range from 0 to 300 (strongest expression) with higher score representing stronger expression, was calculated from the total of each individual intensity of staining (0 \[negative\], 1+ \[weak\], 2+ \[moderate\], 3+ \[strong\]) multiplied by the percentages of cells (0 to 100) that represented that staining.

    Time frame: Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26

  12. Ratio Over Baseline for Skin Biomarker Ki67 Expression

    The Ki67 was one of the skin biomarkers and samples were assayed using IHC method. Ratio over baseline was calculated by dividing the percentage of Ki67 positive cells at each specified time point by baseline value.

    Time frame: Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26

  13. Ratio Over Baseline for Thymidine Kinase (TK) Concentration

    Blood samples were collected to provide serum for the assessments of TK activity. The concentrations of TK were determined using enzyme-linked immunosorbent assay (ELISA) method. Ratio of serum TK concentration at each specified time point over baseline value was presented.

    Time frame: Baseline (Day -1 pre-dose), lead-in phase Day 1 (4, 8, 10, 24, 72, 120 hours post dose), Cycle 1 Day 21 (4, 8, 10, 24, 72, 96, 120 hours post dose), Cycle 2 Day 1 pre-dose

07

Results

Posted Jul 29, 2019

Participant flow

Participant flow — Overall Study
MilestonePalbociclib + Letrozole
Started26
Completed0
Not completed26
Withdrew: Global deterioration of health status1
Withdrew: Objective progression or relapse20
Withdrew: Other2
Withdrew: Participant refused continued treatment for reason other than adverse event3

Outcome measures

PrimarySingle-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib

Cmax of palbociclib in the single-dose part (lead-in phase) was observed directly from data.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib
nanograms per milliliter (ng/mL)Palbociclib + Letrozole
Single-dose Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) for Palbociclib82.14 ± 25
PrimarySingle-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib

Tmax for palbociclib in the single-dose part (lead-in phase) was observed directly from data as time of first occurrence.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Median · hours
Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib
hoursPalbociclib + Letrozole
Single-dose PK: Time to Reach Maximum Plasma Concentration (Tmax) for Palbociclib7.94 (3.97 to 10.0)
PrimarySingle-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib

AUC10 for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, and 10 hours post dose
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*hr/mL)
Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib
nanograms*hour per milliliter (ng*hr/mL)Palbociclib + Letrozole
Single-dose PK: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Time 10 Hours (AUC10) for Palbociclib498.3 ± 28
PrimarySingle-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib

AUC24 is AUCtau, where the dosing interval (tau) is 24 hours. AUC24 in the single-dose part (lead-in phase) for palbociclib was obtained by linear/log trapezoidal method.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose
Reported as:
Geometric mean · ng*hr/mL
Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib
ng*hr/mLPalbociclib + Letrozole
Single-dose PK: AUC From Time 0 to the Time 24 Hours (AUC24) for Palbociclib1217 ± 22
PrimarySingle-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib

AUClast for palbociclib in the single-dose part (lead-in phase) was obtained by linear/log trapezoidal method.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Geometric mean · ng*hr/mL
Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib
ng*hr/mLPalbociclib + Letrozole
Single-dose PK: AUC From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Palbociclib2308 ± 27
PrimarySingle-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib

AUCinf for palbociclib in the single-dose part (lead-in phase) was calculated as AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the rate constant for terminal phase obtained by linear regression of the log-linear concentration-time curve.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Geometric mean · ng*hr/mL
Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib
ng*hr/mLPalbociclib + Letrozole
Single-dose PK: AUC From Time 0 Extrapolated to Infinite Time (AUCinf) for Palbociclib2386 ± 27
PrimarySingle-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib

Kel for palbociclib in the single-dose part (lead-in phase) was obtained by linear regression of the log-linear concentration-time curve.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Mean · per hour
Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib
per hourPalbociclib + Letrozole
Single-dose PK: Rate Constant for Terminal Phase (Kel) for Palbociclib0.03006 ± 0.00420
PrimarySingle-dose PK: Mean Residence Time (MRT) for Palbociclib

MRT for palbociclib in the single-dose part (lead-in phase) was calculated as AUMCinf/AUCinf, where AUMCinf was area under the first moment curve from time 0 to infinity.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Mean · hours
Single-dose PK: Mean Residence Time (MRT) for Palbociclib
hoursPalbociclib + Letrozole
Single-dose PK: Mean Residence Time (MRT) for Palbociclib34.42 ± 4.32
PrimarySingle-dose PK: Terminal Half-Life (t1/2) for Palbociclib

t1/2 for palbociclib in the single-dose part (lead-in phase) was calculated as Loge(2)/kel.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Mean · hours
Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib
hoursPalbociclib + Letrozole
Single-dose PK: Terminal Half-Life (t1/2) for Palbociclib23.46 ± 3.14
PrimarySingle-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib

CL/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/AUCinf.

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Geometric mean · liters per hour (L/hr)
Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib
liters per hour (L/hr)Palbociclib + Letrozole
Single-dose PK: Apparent Oral Clearance (CL/F) for Palbociclib52.40 ± 27
PrimarySingle-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib

Vz/F for palbociclib in the single-dose part (lead-in phase) was calculated as Dose/(AUCinf \* kel).

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose
Reported as:
Geometric mean · liters
Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib
litersPalbociclib + Letrozole
Single-dose PK: Apparent Volume of Distribution (Vz/F) for Palbociclib1758 ± 21
PrimaryMultiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib

Css,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Reported as:
Geometric mean · ng/mL
Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib
ng/mLPalbociclib + Letrozole
Multiple-dose PK: Maximum Plasma Concentration at Steady State (Css,Max) for Palbociclib139.7 ± 28
PrimaryMultiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib

Css,min of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Reported as:
Geometric mean · ng/mL
Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib
ng/mLPalbociclib + Letrozole
Multiple-dose PK: Minimum Plasma Concentration at Steady State (Css,Min) for Palbociclib67.55 ± 46
PrimaryMultiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib

AUCss,tau of palbociclib in the multiple-dose part (Cycle 1) was determined by linear/log trapezoidal method.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Reported as:
Geometric mean · ng*hr/mL
Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib
ng*hr/mLPalbociclib + Letrozole
Multiple-dose PK: AUC Within a Dosing Interval of Tau (=24 Hours) at Steady State (AUCss,Tau) for Palbociclib2501 ± 29
PrimaryMultiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib

Css,av of palbociclib in the multiple-dose part (Cycle 1) was calculated as AUCss,tau/tau, where tau was 24 hours.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Reported as:
Geometric mean · ng/mL
Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib
ng/mLPalbociclib + Letrozole
Multiple-dose PK: Average Plasma Concentration at Steady State (Css,av) for Palbociclib104.2 ± 29
PrimaryMultiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib

Tss,max of palbociclib in the multiple-dose part (Cycle 1) was observed directly from data as time of first occurrence within tau (=24 hours) at steady state.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Reported as:
Median · hours
Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib
hoursPalbociclib + Letrozole
Multiple-dose PK: Time to Reach Maximum Plasma Concentration at Steady State (Tss,Max) for Palbociclib6.05 (3.97 to 10.0)
PrimaryMultiple-dose PK: Vz/F for Palbociclib

Vz/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/(AUCss,tau \* kel), where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state and kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Reported as:
Geometric mean · Liters
Multiple-dose PK: Vz/F for Palbociclib
LitersPalbociclib + Letrozole
Multiple-dose PK: Vz/F for Palbociclib1910 ± 29
PrimaryMultiple-dose PK: t1/2 for Palbociclib

t1/2 of palbociclib in the multiple-dose part (Cycle 1) was calculated as ln (2)/kel, where kel was the terminal phase rate constant following multiple-dose calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Reported as:
Mean · hours
Multiple-dose PK: t1/2 for Palbociclib
hoursPalbociclib + Letrozole
Multiple-dose PK: t1/2 for Palbociclib27.26 ± 3.19
PrimaryMultiple-dose PK: CL/F for Palbociclib

CL/F of palbociclib in the multiple-dose part (Cycle 1) was calculated as Dose/AUCss,tau, where AUCss,tau was the AUC within a dosing interval of tau (=24 hours) at steady state.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Reported as:
Geometric mean · L/hr
Multiple-dose PK: CL/F for Palbociclib
L/hrPalbociclib + Letrozole
Multiple-dose PK: CL/F for Palbociclib49.97 ± 29
PrimaryMultiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib

PTF of palbociclib in the multiple-dose part (Cycle 1) was determined as (Css,max - Css,min)/Css,av. Css,max and Css,min were observed directly from data while Css,av was calculated as AUCss,tau/tau, where tau was 24 hours.

Time frame:
Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24, 48, 72, 96, 120 hours post dose on Day 21
Reported as:
Geometric mean · ratio
Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib
ratioPalbociclib + Letrozole
Multiple-dose PK: Peak to Trough Fluctuation at Steady State (PTF) for Palbociclib0.6652 ± 27
PrimaryObserved Accumulation Ratio (Rac) for Palbociclib

Rac of palbociclib was determined as AUCss,tau/AUCsd,tau, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCsd,tau was AUC24 from single-dose part (lead-in phase).

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, and 24 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, and 24 hours post dose on Day 21
Reported as:
Geometric mean · ratio
Observed Accumulation Ratio (Rac) for Palbociclib
ratioPalbociclib + Letrozole
Observed Accumulation Ratio (Rac) for Palbociclib2.042 ± 27
PrimarySteady State Accumulation Ratio (Rss) for Palbociclib

Rss of palbociclib was calculated as AUCss,tau/AUCinf, where AUCss,tau (tau=24 hours) was from multiple-dose part (Cycle 1) and AUCinf was from single-dose part (lead-in phase).

Time frame:
Lead-in phase: Day 1 pre-dose, 2, 4, 6, 8, 10, 24, 48, 72, 96 and 120 hours post dose; Cycle 1: pre-dose on Day 19, Day 20, Day 21, and 2, 4, 6, 8, 10, 24 hours post dose on Day 21
Reported as:
Geometric mean · ratio
Steady State Accumulation Ratio (Rss) for Palbociclib
ratioPalbociclib + Letrozole
Steady State Accumulation Ratio (Rss) for Palbociclib1.036 ± 26
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator.

Time frame:
From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPalbociclib + Letrozole
Treatment-emergent AEs (all causalities)26
Treatment-emergent AEs (treatment-related)26
Treatment-emergent SAEs (all causalities)4
Treatment-emergent SAEs (treatment-related)1
SecondaryNumber of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade

An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or increasing in severity on or after the first dose of investigational product administration. AEs included both SAEs and non-serious AEs. Causality to study treatment was determined by the investigator. AEs were graded by NCI CTCAE version 4.0: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE.

Time frame:
From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent AEs by Maximum National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade
ParticipantsPalbociclib + Letrozole
Grade 10
Grade 25
Grade 316
Grade 45
Grade 50
SecondaryNumber of Participants With Laboratory Test Abnormalities

The number of participants with the following laboratory test abnormalities meeting any of the Grades 1 to 4 criteria per the NCI CTCAE (version 4.0) is summarized: anemia, lymphopenia, neutropenia, platelet count decreased, white blood cell (WBC) decreased, alanine aminotransferase (ALT) increased, alkaline phosphatase increased, aspartate aminotransferase (AST) increased, bilirubin (total) increased, creatinine increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4=life-threatening. One participant might had more than 1 laboratory test abnormality.

Time frame:
From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsPalbociclib + Letrozole
Anemia23
Lymphopenia19
Neutropenia26
Platelet count decreased20
WBC decreased25
ALT increased11
Alkaline phosphatase increased12
AST increased18
Bilirubin (total) increased4
Creatinine increased25
Hypercalcemia1
Hyperglycemia10
Hyperkalemia0
Hypermagnesemia2
Hypernatremia6
Hypoalbuminemia11
Hypocalcemia11
Hypoglycemia0
Hypokalemia6
Hypomagnesemia5
Hyponatremia6
SecondaryNumber of Participants Meeting the Categorical Summarization Criteria for QTcF and QTcB Parameters

QT interval (time from electrocardiogram \[ECG\] Q wave and the end of the T wave corresponding to electrical systole) corrected for heart rate using Fridericia's formula was QTcF and QT interval corrected for heart rate using Bazett's formula was QTcB. Categorical summarization criteria for QTcF and QTcB were as follows: 1) maximum absolute value of \<450 milliseconds (msec), \>=450 to \<=480 msec, \>=481 to \<=500 msec, or \>=500 msec; 2) maximum increase from baseline of \<30 msec, \>=30 to \<60 msec, or \>=60 msec. One participant could be reported under more than 1 categorical summarization criteria for QTcF and QTcB Parameters.

Time frame:
From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks)
Reported as:
Count of participants · Participants
Number of Participants Meeting the Categorical Summarization Criteria for QTcF and QTcB Parameters
ParticipantsPalbociclib + Letrozole
Maximum QTcF <450 msec21
Maximum QTcF >=450 to <=480 msec4
Maximum QTcF >=481 to <=500 msec1
Maximum QTcF >500 msec0
Maximum increase in QTcF <30 msec17
Maximum increase in QTcF >=30 to <60 msec9
Maximum increase in QTcF >=60 msec0
Maximum QTcB <450 msec9
Maximum QTcB >=450 to <=480 msec16
Maximum QTcB >=481 to <=500 msec0
Maximum QTcB >500 msec1
Maximum increase in QTcB <30 msec16
Maximum increase in QTcB >=30 to <60 msec9
Maximum increase in QTcB >=60 msec1
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from Cycle 1 Day 1 (C1D1) to date of first documentation of disease progression (PD) or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsPalbociclib + Letrozole
Progression-Free Survival (PFS)18.6 (6.5 to 27.7)
SecondaryPercentage of Participants Achieving Objective Response (Objective Response Rate [ORR])

ORR was the percentage of participants with an objective response (complete response \[CR\] or partial response \[PR\]). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions.

Time frame:
From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Objective Response (Objective Response Rate [ORR])
Percentage of participantsPalbociclib + Letrozole
Percentage of Participants Achieving Objective Response (Objective Response Rate [ORR])19.2 (6.6 to 39.4)
SecondaryPercentage of Participants Achieving Disease Control (Disease Control Rate [DCR])

Disease control (DC) = CR, PR or stable disease (SD) \>= 24 weeks according to RECIST version 1.1 recorded from C1D1 until disease progression or death due to any cause. CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). SD: Does not qualify for CR, PR or progression. PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or appearance of new unequivocal malignant lesions.

Time frame:
From C1D1 until disease progression or death due to any cause, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Disease Control (Disease Control Rate [DCR])
Percentage of participantsPalbociclib + Letrozole
Percentage of Participants Achieving Disease Control (Disease Control Rate [DCR])65.4 (44.3 to 82.8)
SecondaryDuration of Response

Duration of response was the time from first documentation of CR or PR to date of first documentation of PD or death for the participants with an objective response (CR or PR). Per RECIST (version 1.1). CR: complete disappearance of all target lesions except nodal disease or disappearance of all non-target lesions and normalization of tumor marker levels. All target nodes/lymph nodes must decrease to normal size (\<10 mm short axis); PR: \>=30% decrease under baseline of the sum of diameters of all target measurable lesions (short diameter=sum for target nodes; longest diameter=sum for all other target lesions). PD: 20% increase in sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm or unequivocal progression of pre-existing non-target lesions or appearance of new unequivocal malignant lesions. Kaplan-Meier method was used.

Time frame:
From first documentation of CR or PR to date of first documentation of objective progression or death, whichever occurred first (up to maximum of 471 weeks of treatment exposure)
Reported as:
Median · Months
Duration of Response
MonthsPalbociclib + Letrozole
Duration of Response25.1 (8.3 to NA)
Secondary1-Year PFS Probability

PFS was defined as the time from C1D1 to date of first documentation of PD or death due to any cause, whichever occurred first. Documentation of progression was by objective disease assessment as defined by the RECIST (version 1.1). PD was defined as a \>=20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 millimeter (mm); or unequivocal progression of pre-existing lesions for non-target disease; or appearance of new unequivocal malignant lesions. One-year PFS probability was defined as the probability (expressed as percentage) of PFS at 1 year after C1D1. PFS probability was determined using the Kaplan-Meier method.

Time frame:
1 year
Reported as:
Number · Percentage probability
1-Year PFS Probability
Percentage probabilityPalbociclib + Letrozole
1-Year PFS Probability57.5 (35.3 to 74.5)
SecondaryTrough Plasma Concentration of Letrozole

Plasma samples were analyzed for letrozole concentrations using a validated, sensitive and specific high-performance liquid chromatography tandem mass spectrometric (HPLC/MS/MS) method.

Time frame:
pre-dose of Cycle 1 Days 19, 20, 21 and Cycle 2 Day 1
Reported as:
Median · nanograms per milliliter (ng/mL)
Trough Plasma Concentration of Letrozole
nanograms per milliliter (ng/mL)Palbociclib + Letrozole
Cycle 1 Day 19 pre-dose83.70 (30.8 to 134)
Cycle 1 Day 20 pre-dose83.85 (41.4 to 141)
Cycle 1 Day 21 pre-dose85.30 (38.2 to 134)
Cycle 2 Day 1 pre-dose97.40 (48.8 to 282)
SecondaryRatio Over Baseline for Skin Biomarker Phosphorylated Retinoblastoma Protein (pRb) Expression

The pRb was one of the skin biomarkers and samples were assayed using immunohistochemistry (IHC) method. Ratio over baseline was calculated by dividing the H-score value for pRb at each specified time point by baseline value. The H-score value, which could range from 0 to 300 (strongest expression) with higher score representing stronger expression, was calculated from the total of each individual intensity of staining (0 \[negative\], 1+ \[weak\], 2+ \[moderate\], 3+ \[strong\]) multiplied by the percentages of cells (0 to 100) that represented that staining.

Time frame:
Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26
Reported as:
Geometric mean · ratio
Ratio Over Baseline for Skin Biomarker Phosphorylated Retinoblastoma Protein (pRb) Expression
ratioPalbociclib + Letrozole
Lead-in phase Day 10.644 ± 56.34
Lead-in phase Day 20.523 ± 92.28
Cycle 1 Day 210.535 ± 108.77
Cycle 1 Day 220.773 ± 57.77
Cycle 1 Day 230.799 ± 91.59
Cycle 1 Day 241.493 ± 103.46
Cycle 1 Day 251.165 ± 99.39
Cycle 1 Day 262.164 ± 87.80
SecondaryRatio Over Baseline for Skin Biomarker Ki67 Expression

The Ki67 was one of the skin biomarkers and samples were assayed using IHC method. Ratio over baseline was calculated by dividing the percentage of Ki67 positive cells at each specified time point by baseline value.

Time frame:
Baseline (Day -1), lead-in phase Days 1 and 2, Cycle 1 Days 21, 22, 23, 24, 25, 26
Reported as:
Geometric mean · ratio
Ratio Over Baseline for Skin Biomarker Ki67 Expression
ratioPalbociclib + Letrozole
Lead-in phase Day 10.985 ± 42.32
Lead-in phase Day 20.868 ± 64.99
Cycle 1 Day 210.495 ± 107.24
Cycle 1 Day 220.408 ± 135.34
Cycle 1 Day 230.599 ± 80.00
Cycle 1 Day 240.832 ± 42.34
Cycle 1 Day 250.920 ± 85.52
Cycle 1 Day 261.301 ± 61.26
SecondaryRatio Over Baseline for Thymidine Kinase (TK) Concentration

Blood samples were collected to provide serum for the assessments of TK activity. The concentrations of TK were determined using enzyme-linked immunosorbent assay (ELISA) method. Ratio of serum TK concentration at each specified time point over baseline value was presented.

Time frame:
Baseline (Day -1 pre-dose), lead-in phase Day 1 (4, 8, 10, 24, 72, 120 hours post dose), Cycle 1 Day 21 (4, 8, 10, 24, 72, 96, 120 hours post dose), Cycle 2 Day 1 pre-dose
Reported as:
Geometric mean · ratio
Ratio Over Baseline for Thymidine Kinase (TK) Concentration
ratioPalbociclib + Letrozole
Lead-in phase Day 1, 4 hours post dose0.780 ± 44.69
Lead-in phase Day 1, 8 hours post dose0.774 ± 43.65
Lead-in phase Day 1, 10 hours post dose0.733 ± 49.67
Lead-in phase Day 1, 24 hours post dose0.702 ± 48.93
Lead-in phase Day 1, 72 hours post dose0.530 ± 50.14
Lead-in phase Day 1, 120 hours post dose0.598 ± 74.40
Cycle 1 Day 21, 4 hours post dose0.260 ± 172.41
Cycle 1 Day 21, 8 hours post dose0.236 ± 191.22
Cycle 1 Day 21, 10 hours post dose0.236 ± 187.02
Cycle 1 Day 21, 24 hours post dose0.247 ± 164.37
Cycle 1 Day 21, 48 hours post dose0.244 ± 166.61
Cycle 1 Day 21, 72 hours post dose0.268 ± 163.67
Cycle 1 Day 21, 96 hours post dose0.292 ± 176.92
Cycle 1 Day 21, 120 hours post dose0.455 ± 334.32
Cycle 2 Day 1, pre-dose1.069 ± 248.43

Adverse events

Collected over From first dose of study medication up to 28 days after last dose of study medication (up to maximum of 475 weeks, maximum treatment exposure = 471 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Palbociclib + Letrozole0/26 (0%)4/26 (15.4%)26/26 (100%)
Most frequent serious events
Most frequent serious events
EventPalbociclib + Letrozole
Drug-induced liver injuryHepatobiliary disorders1/26
PneumoniaInfections and infestations1/26
AbscessInfections and infestations1/26
OsteomyelitisInfections and infestations1/26
Pneumonia viralInfections and infestations1/26
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPalbociclib + Letrozole
Neutrophil count decreasedInvestigations16/26
Platelet count decreasedInvestigations15/26
White blood cell count decreasedInvestigations15/26
AnaemiaBlood and lymphatic system disorders13/26
LeukopeniaBlood and lymphatic system disorders11/26
Aspartate aminotransferase increasedInvestigations11/26
NeutropeniaBlood and lymphatic system disorders10/26
Alanine aminotransferase increasedInvestigations10/26
Haemoglobin decreasedInvestigations6/26
FatigueGeneral disorders5/26

Baseline characteristics

All enrolled participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Palbociclib + Letrozole
Mean50.8 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Palbociclib + Letrozole
Female26
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Palbociclib + Letrozole
Asian26
08

Study locations

7 sites
  • Beijing Cancer Hospital/Oncology department
    Beijing, Beijing Municipality 100142, China
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Guangdong General Hospital/Department of Breast Surgery
    Guangzhou, Guangdong 510080, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
  • The first hospital of jilin university
    Changchun, Jilin 130021, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Beijing, 100021, China
09

References and documents

Publications

  • Yu Y, Sun W, Liu Y, Wang D. Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer. J Clin Pharmacol. 2022 Mar;62(3):376-384. doi: 10.1002/jcph.1971. Epub 2021 Nov 16. PubMed 34554584 ↗
  • Xu B, Li H, Zhang Q, Sun W, Yu Y, Li W, Wang S, Liao N, Shen P, Liu Y, Huang Y, Linn C, Zhao H, Jiang J, Wang D. Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. Cancer Chemother Pharmacol. 2021 Jul;88(1):131-141. doi: 10.1007/s00280-021-04263-9. Epub 2021 Apr 9. PubMed 33835229 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jul 2018, 34 months.

Results were first posted in Jul 2019, 11 months after primary completion.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 34 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2015
First posted
Jul 15, 2015
StartActual
Sep 11, 2015
Primary completionActual
Jul 31, 2018
CompletionActual
Dec 24, 2024
Results first posted
Jul 29, 2019
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02499146
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 15, 2015
Start date
Sep 11, 2015
Primary completion
Jul 31, 2018
Completion
Dec 24, 2024
Results posted
Jul 29, 2019
Last update
Feb 11, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion